Watch live 🔴
We are now starting our regular press briefing on EMA’s response to #COVID19 and other public health emergencies.
Don’t miss our tweets during the press briefing. Follow #EMAPresser.
🧵👇
https://www.youtube.com/watch?v=v42Biekaazc
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625842771130044418
COVID-19 still poses a significant burden on healthcare systems. The low uptake of #booster doses among vulnerable groups is a concern for #PublicHealth. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843339017830400
We encourage elderly people, pregnant persons and immunocompromised patients who have not been revaccinated against #COVID with an #AdaptedVaccine, to do so.
#UnitedInProtection #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843660649598976
We are discussing with international partners criteria and the process for an update of the #COVID19Vaccines. 💉
Vaccination campaigns could take place primarily once a year and at the start of the winter❄️. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844608402849793
The assessment of #COVID19Vaccine HIPRA 💉 is progressing, and we hope to conclude it very soon. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844808404049920
We collaborate closely with @WHO to enable access to safe and effective vaccines in many countries around the 🌍. #UnitedInProtection #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844973110235138
We are evaluating an #RSV vaccine for older adults with a possible recommendation in the next months.
There is a need to better protect vulnerable groups against respiratory viruses 🦠 that might cause disease waves in winter. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845192136720385
❗️ #LongCovid is high on our agenda.
Current focus of many researchers is characterisation of the disease burden & clinical symptoms.
We are engaging with developers to discuss the design of clinical studies & what concrete measurable outcomes may look like.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845560493178880
#RealWorldData on the #Mpox vaccine show that it is effective, especially after 2⃣ doses.
Discussions are ongoing with developers of other vaccines for Mpox and other viruses of the same type.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845803758518273
EMA is in contact with developers of mucosal #COVID19vaccines. We are ready to discuss emerging data from the vaccines that have already been deployed in India 🇮🇳 and China 🇨🇳. #EMAPresser
🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844975073214472